Structure Therapeutics Q2 net loss $26M; cash $927M; GSBR-1290 Phase 2b on track Q4 2024

Structure Therapeutics Inc.

2024-Q2 EPS reported -$0.36

Q2 2024 net loss $26.0M vs $23.3M in Q2 2023; R&D expenses $22.1M, G&A $11.3M.
Cash, equivalents and short-term investments $927.1M expected to fund operations through at least 2027.
GSBR-1290 Phase 2b obesity study on track to initiate in Q4 2024; Phase 2a showed 6.2% placebo-adjusted weight loss at 12 weeks.
Amylin receptor agonist development candidate expected to be selected in Q4 2024; GIPR candidate expected H1 2025.
Phase 1 trial of LTSE-2578 (LPA1R antagonist for IPF) initiated in June 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.